1
|
Landolff Q, Quillot M, Picard F, Henry P, Sideris G, Bizeau O, Piot C, Jouve B, Rischner J, Mejri M, Charmasson C, Lasserre R, Pouliquen H, Joseph T, Monsegu J, Karsenty B, Martin Yuste V, Richet N, Lapeyre G, Beverelli F, Beygui F, Koning R. In-Hospital and 1-Year Clinical Results from the French Registry Using Polymer-Free Sirolimus-Eluting Stents in Acute Coronary Syndrome and Stable Coronary Artery Disease. J Interv Cardiol 2023; 2023:8907315. [PMID: 38125031 PMCID: PMC10733033 DOI: 10.1155/2023/8907315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 11/07/2023] [Accepted: 11/24/2023] [Indexed: 12/23/2023] Open
Abstract
Objectives The aim of this postmarket clinical study was to assess the safety and efficacy of the latest generation polymer-free sirolimus-eluting stents (PF-SES) in an all-comers population comparing outcomes in stable coronary artery disease (CAD) versus acute coronary syndrome (ACS) in France. Background The efficacy and safety of the first-generation PF-SES have already been demonstrated by randomized controlled trials and "all-comers" observational studies. Methods For this all-comers observational, prospective, multicenter study, 1456 patients were recruited in 22 French centers. The primary endpoint was target lesion revascularization (TLR) rate at 12 months and secondary endpoints included major adverse cardiac events (MACE) and bleeding. Results 895 patients had stable CAD and 561 had ACS. At 12 months, 2% of patients had a TLR, with similar rates between stable CAD and ACS (1.9% vs 2.2%, p = 0.7). The overall MACE rate was 5.2% with an expected higher rate in patients with ACS as compared to those with stable CAD (7.3% vs 3.9%, p = 0.007). The overall bleeding event rate was 4.5%, with similar rates in stable CAD as compared to ACS patients (3.8% vs 5.6%, p = 0.3). Dual antiplatelet therapy (DAPT) interruptions prior to the recommended duration occurred in 41.7% of patients with no increase in MACE rates as compared to patients who did not prematurely interrupt DAPT (3.9% vs 6.1%, p = 0.073). Conclusions The latest generation PF-SES is associated with low clinical event rates in these all-comers patients. There was a high rate of prematurely terminated DAPT, without any effect on MACE at 12 months. This trial is registered with NCT03809715.
Collapse
Affiliation(s)
| | - Marine Quillot
- Department of Cardiology, Centre Hospitalier Henri Duffaut, Avignon, France
| | - Fabien Picard
- Department of Cardiology, Hôpital Cochin-Port Royal, AP-HP, Paris, France
| | - Patrick Henry
- Department of Cardiology, Hôpital Lariboisière- Fernand Widal, AP-HP, Paris, France
| | - Georgios Sideris
- Department of Cardiology, Hôpital Lariboisière- Fernand Widal, AP-HP, Paris, France
- Department of Cardiology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
| | - Olivier Bizeau
- Department of Cardiology, Centre Hospitalier Régional d'Orléans Hôpital de la source, Orléans, France
| | - Christophe Piot
- Department of Cardiology, Clinique du Millénaire, Montpellier, France
| | - Bernard Jouve
- Department of Cardiology, Centre Hospitalier d'Aix en Provence, Aix en Provence, France
| | - Jérôme Rischner
- Department of Cardiology, Hôpital Albert Schweitzer, Colmar, France
| | - Mourad Mejri
- Department of Cardiology, Centre Hospitalier de Saint-Malo, Saint-Malo, France
| | | | - Raphael Lasserre
- Department of Cardiology, Centre Hospitalier de Pau, Pau, France
| | - Hervé Pouliquen
- Department of Cardiology, CHD les Oudairies, La Roche sur Yon, France
| | - Thierry Joseph
- Department of Cardiology, Centre Hospitalier de Cornouaille, Quimper, France
| | | | - Bernard Karsenty
- Department of Cardiology, Hopital Privé Saint-Martin, Pessac, France
| | | | - Nicolas Richet
- Department of Cardiology, Centre Hospitalier de Valence, Valence, France
| | - Guy Lapeyre
- Department of Cardiology, Clinique Claude Bernard, Albi, France
| | - Fabrizio Beverelli
- Department of Cardiology, Clinique Ambroise Paré, Neuilly sur Seine, France
| | | | - René Koning
- Department of Cardiology, Clinique Saint Hilaire, Rouen, France
| |
Collapse
|
2
|
Beijk MAM. Special Issue "Clinical Frontiers in Percutaneous Coronary Intervention". J Clin Med 2023; 12:5969. [PMID: 37762910 PMCID: PMC10531543 DOI: 10.3390/jcm12185969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Accepted: 09/13/2023] [Indexed: 09/29/2023] Open
Abstract
In the last decade, significant advancements have been made in the field of percutaneous coronary interventions (PCIs) with the development of new devices and drugs, the application of new technology and the utilization of artificial intelligence/machine learning, and new indications for revascularization [...].
Collapse
Affiliation(s)
- Marcel A M Beijk
- Department of Cardiology, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
| |
Collapse
|